Evidence map›Paper›PMID 41219476›Full record

ArticleBJC reports2025

Introduction of whole genome sequencing as NHS standard of care for glioma patients in two neurosurgical oncology centres: West Midlands.

Victoria Wykes, Erminia Albanese, Vassili Crispi, Sana Manan, Taufiq Khan, Naomi Cole, Christine Bennett, Lowri Hughes, Natasha Vafadar, Vinton Cheng and 4 more

Abstract read
In one paragraph

Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Victoria WykesDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. v.wykes@bham.ac.uk.ORCID http://orcid.org/0000-0002-2998-8919
Erminia AlbaneseDepartment of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK.
Vassili CrispiDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Sana MananDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Taufiq KhanDepartment of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK.
Naomi ColeDepartment of Neuro-Oncology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Christine BennettDepartment of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK.
Lowri HughesWest Midlands Regional Genomics Laboratory, Birmingham and Children's NHS Foundation Trust, Birmingham, UK.
Natasha VafadarWest Midlands Regional Genomics Laboratory, Birmingham and Children's NHS Foundation Trust, Birmingham, UK.
Vinton ChengDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Ute PohlDepartment of Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Manoj RaghavanDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Yvonne WallisWest Midlands Regional Genomics Laboratory, Birmingham and Children's NHS Foundation Trust, Birmingham, UK.
Colin WattsDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. c.watts.2@bham.ac.uk.ORCID http://orcid.org/0000-0003-3531-8791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe challenges of introducing Whole Genome Sequencing (WGS) as NHS standard of care for patients with glioma are reviewed.

methodsPatients undergoing glioma surgery with WGS sampling were identified retrospectively from WGS reports between 01/01/2022-30/12/2023. Data including demographics, integrated molecular diagnosis, time through critical pathway steps per calendar quarter (Q) and WGS variants were captured from electronic health records.

results146 glioma samples were analysed. 91% of patients underwent craniotomy and 1 cm

conclusionsWGS is feasible for patients undergoing biopsy or craniotomy. NHS infrastructural resources and improvement of WGS technologies are required to improve turnaround time and ensure equitable access for all patients with glioma.

Identifiers

PMID41219476
PMCPMC12606122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.